The respected Medical Oncology leader brings extensive experience as TD2 continues its strategic growth.

SCOTTSDALE, ARIZONA, UNITED STATES, October 5, 2022 / — Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the addition of Dr. Alan Miller as their new Chief Medical Officer. Prior to joining TD2, Dr. Miller was Chief Medical Director of Oncology and Associate Chief Medical Director of Clinical Research at SCL Health.

Dr. Miller obtained his Ph.D. at Roswell Park (SUNY) and his M.D. from the University of Miami School of Medicine. Trained as a medical oncologist, he was also the Associate Senior Vice President for Health Sciences for Tulane Cancer Center, where he navigated the challenges of rebuilding and re-establishing the university and hospital following Hurricane Katrina. He also served as Cancer Center Director of the Baylor Sammons Cancer Center where he brought together a not-for-profit healthcare system and private oncology practices to form an oncology network across north Texas. Additionally, Dr. Miller built a larger system-wide oncology network while at SCL Health and established a system-wide clinical trials infrastructure for a multi-state healthcare system. He also serves as a Board Member for the American Cancer Society Denver and Rocky Mountain Oncology Society.

“Dr. Miller has extensive experience across many cancer types and new medicine development.” said Dr. Stephen Gately, President, and CEO of TD2. “He will be an incredible resource to both our internal teams, as well as clients, as we continue our strategic growth.”

About TD2

TD2 is a leader in precision oncology, providing innovative services for improved drug development. Using a dedicated, expert team with broad experience and understanding in cancer medicine, TD2 is uniquely positioned to support accelerated development of novel therapeutics. Rigorous and high-throughput translational preclinical development services, combined with regulatory affairs expertise, enables customized clinical trial design and execution. The broad suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process with the ultimate goal of accelerating patient access to promising treatments. For more information, visit

Kristen Dempsey
Translational Drug Development (TD2)
+1 314-920-6252

Climbing the Mountain: Current Challenges in Early Phase Oncology Clinical Trials

Oncology clinical trials are at the forefront of medical research, paving the way for innovative treatments and advancements in the fight against...

Read more +

The Significance of Preclinical Evaluation in CAR T-cell Therapy for Solid and Hematologic Tumors

Cell therapy has emerged as a promising approach in the field of cancer treatment, and chimeric antigen receptor (CAR) T-cell therapy has shown...

Read more +

Advancing Preclinical Cancer Research Through Metabolomics: Key Strategies for Biomarker Identification and Drug-Target Analysis in Immuno-Oncology

The dynamic field of cancer research is continually evolving, driven by the pursuit of deeper understanding and novel therapeutic strategies against...

Read more +


Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.

Skip to content